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Abstract
Background: Exposure to particulate matter is a risk factor for cardiopulmonary disease but the
underlying molecular mechanisms remain poorly understood. In the present study we sought to
investigate the cardiopulmonary responses on spontaneously hypertensive rats (SHRs) following
inhalation of UfCPs (24 h, 172 μg·m-3), to assess whether compromised animals (SHR) exhibit a
different response pattern compared to the previously studied healthy rats (WKY).
Methods: Cardiophysiological response in SHRs was analyzed using radiotelemetry. Blood
pressure (BP) and its biomarkers plasma renin-angiotensin system were also assessed. Lung and
cardiac mRNA expressions for markers of oxidative stress (hemeoxygenase-1), blood coagulation
(tissue factor, plasminogen activator inhibitor-1), and endothelial function (endothelin-1, and
endothelin receptors A and B) were analyzed following UfCPs exposure in SHRs. UfCPs-mediated
inflammatory responses were assessed from broncho-alveolar-lavage fluid (BALF).
Results: Increased BP and heart rate (HR) by about 5% with a lag of 1–3 days were detected in
UfCPs exposed SHRs. Inflammatory markers of BALF, lung (pulmonary) and blood (systemic) were
not affected. However, mRNA expression of hemeoxygenase-1, endothelin-1, endothelin
receptors A and B, tissue factor, and plasminogen activator inhibitor showed a significant induction
(~2.5-fold; p < 0.05) with endothelin 1 being the maximally induced factor (6-fold; p < 0.05) on the
third recovery day in the lungs of UfCPs exposed SHRs; while all of these factors – except
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Particle and Fibre Toxicology 2008, 5:19 http://www.particleandfibretoxicology.com/content/5/1/19hemeoxygenase-1 – were not affected in cardiac tissues. Strikingly, the UfCPs-mediated altered BP
is paralleled by the induction of renin-angiotensin system in plasma.
Conclusion: Our finding shows that UfCPs exposure at levels which does not induce detectable
pulmonary neutrophilic inflammation, triggers distinct effects in the lung and also at the systemic
level in compromised SHRs. These effects are characterized by increased activity of plasma renin-
angiotensin system and circulating white blood cells together with moderate increases in the BP,
HR and decreases in heart rate variability. This systemic effect is associated with pulmonary, but
not cardiac, mRNA induction of biomarkers reflective of oxidative stress; activation of
vasoconstriction, stimulation of blood coagulation factors, and inhibition of fibrinolysis. Thus,
UfCPs may cause cardiovascular and pulmonary impairment, in the absence of detectable
pulmonary inflammation, in individuals suffering from preexisting cardiovascular diseases.
Background
Epidemiological studies have identified exposure to ele-
vated concentrations of ultrafine particles (UFPs; < 100
nm) in the air as a risk factor for the exacerbation of
ischemic heart disease and congestive heart failure with
specific physiological end points like arrhythmias,
reduced heart-rate variability (HRV), elevated heart rate
(HR) and atherosclerosis in adults [1-4]. However, the
underlying pathophysiologcal mechanisms of airborne
UFPs mediated cardiopulmonary mortality and morbid-
ity are complex and remain to a large extent unexplored
[5,6]. Although humans have been exposed to airborne
UFPs throughout evolution, such exposure has increased
dramatically over the last decades mainly due to increased
emissions of combustion derived UFPs, e.g. from motor
vehicles [7]. Thus, specific information about the molecu-
lar and pathophysiologcal mechanism involved in the car-
diovascular impairments following exposure to UFPs is
urgently required.
Dysfunction of the autonomic nervous system, i.e., an
altered autonomic balance is amongst the recently dis-
cussed plausible biological mechanisms linking UFPs
exposure with increased cardiovascular risk [2,8-10].
Exposure to airborne UFPs may cause a low-grade pulmo-
nary inflammation by inducing the generation of reactive
oxygen species and pro-inflammatory cytokines like TNF-
α, IL-1, IL-6 [11]. This could be associated with increased
plasma viscosity [12]; blood coagulability [13], vascular
and endothelial dysfunction [14,15]. Furthermore, there
are evidences that UFPs deposited in the lung gain access
to the systemic circulation and translocate into extra-pul-
monary organs, such as liver, heart, and brain [16,17].
This may disturb the blood coagulation balance by acti-
vating circulating platelets [18,19] but may also induce
dysfunction in secondary target organs [20,21].
Previous studies from our laboratory [9] focussed on car-
diovascular responses in young and healthy WKY (nor-
motensive) rats following inhalation exposure to ultrafine
carbon particles (UfCPs). The observed transient increase
in HR associated with a decrease in HRV during exposure
suggested an altered sympatho-vagal balance due to neu-
ral pathway activation in response to UfCPs inhalation
[9]. Epidemiological studies have provided evidence that
individuals with cardiovascular disease are at higher risk
when exposed to elevated levels of ambient particles.
Therefore, in this study we sought to investigate cardiop-
ulmonary responses to UfCPs in spontaneously hyperten-
sive rats (SHRs; 6 months), a well established animal
model of human cardiovascular disease and assessed
whether compromised animals (SHR) exhibit a different
response pattern compared to what has been previously
observed in healthy Wistar Kyoto (WKY) rats [9].
Compared to transient increases of HR during UfCPs
exposure followed by a moderate pulmonary neutrophilic
inflammation in WKY rats [9], SHRs demonstrated no
sign of pulmonary neutrophilic inflammation or inflam-
matory mediator release, but obvious increases of HR and
blood pressure (BP) for over a longer period of time after
24 h UfCPs inhalation (a lag of 1–3 days). Our mRNA
expression and other biomarker data show that UfCPs
exposure triggers distinct effects in the pulmonary tissue
and also at the systemic level which can contribute to the
observed cardiovascular impairments. Increases in BP
along with induction of plasma renin-angiotensin system
and increased expression for biomarkers of pulmonary
oxidative stress; endothelial activation, and blood coagu-
lation following exposure to UfCPs in cardiovascular
compromised SHRs support the observed epidemiologi-
cal findings of increased cardiovascular mortality as a
result of exposure to peak ambient ultrafine particles con-
centrations.
Results
Cardiophysiological response assessed by radio 
telemetry
Figure 1 depicts 10-minutes data segments of systolic and
diastolic arterial BP, HR, body temperature (T), and activ-
ity level (Act) of one rat for the time course of baseline
(day 0), exposure (day 1), and recovery (day 2–5) periods.Page 2 of 18
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Circadian rhythmicity of physiological and behavioural parameters of SHRs (n = 1)Figure 1
Circadian rhythmicity of physiological and behavioural parameters of SHRs (n = 1). It shows the diastolic (dBP) and 
systolic (sBP) blood pressure, heart rate (HR), body temperature (T) and physical activity (Act) during basline, exposure and 
recovery periods. The dark period (night time) is indicated by the gray segment. Each data point of every parameter represents 
an average of 10-minutes data segments.
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Particle and Fibre Toxicology 2008, 5:19 http://www.particleandfibretoxicology.com/content/5/1/19The data reflect typical circadian rhythmicity of physiolog-
ical and behavioural (activity) parameters of SHRs as
characterized by elevated BP, HR, T, and Act values during
the dark periods.
Comparison of baseline values between 6 and 7 months
old SHRs indicate that cardiac performance was not
altered by the 4 week time gap between control (6.
months) and exposure (7. months) conditions (Figures 2
a–d). Baseline values of mBP (control/exposure: 176 ±
1.2/177 ± 1.2 mmHg), HR (control/exposure: 320 ± 3.5/
318 ± 3.4 bpm), T (control/exposure: 38.1 ± 0.03/38 ±
0.03°C) and Act (control/exposure: 63.6 ± 1.4/63 ± 0.06
event count) remain unchanged by the 4 week time gap
between control and exposure conditions.
Figures 2a and 2b display mean values (± SE) for mean arte-
rial blood pressure (mBP) and HR during dark periods of
baseline, exposure and recovery. Following 24 h exposure to
UfCPs mBP increased by about 6 mmHg, (control/exposure:
176 ± 2.0/182 ± 2.1 mmHg; about 4%, p < 0.05) on the first
and second day of recovery in exposed SHRs, and returned to
baseline levels on the fourth day of recovery. This is due to
the concurrent increase in systolic (control/exposure: 194 ±
2.8/204 ± 2.5 mmHg) and diastolic BP (control/exposure:
158 ± 1.5/160 ± 1.8 mmHg) with the systolic being more
pronounced. In comparison to the BP response, HR
responded with a lag of one day, it increased on the second
and third day of recovery by about 17 bpm, (control/expo-
sure: 328 ± 3.5/345 ± 3.5 bpm; about 5%, p < 0.05) and
reached baseline values on the fourth day of recovery. UfCP
exposure did not affect body temperature or activity levels of
the animals. Both remained unaffected in UfCPs exposed
SHRs compared to their control (Figures 2c and 2d).
The standard deviation of all normal adjacent sinus intervals
(SDNN), a measure of the overall heart-rate variability
(HRV), was decreased by about 30% (p < 0.05) during the
recovery period on the second and third day (Figure 3). The
square root of the mean of squared differences between adja-
cent normal to normal intervals (RMSSD) and the low-fre-
quency to high-frequency ratio (LF/HF), showed a
comparable response as SDNN, but failed to be statistically
significant (Figure 3). No individual changes in absolute LF
(baseline: 21.5 ± 1.13 nu; second recovery day: 17.6 ± 1.3 nu;
third recovery day: 18.1 ± 0.89 nu) and HF (baseline: 70.2 ±
1.9 nu; second recovery day: 67.8 ± 2.8 nu; third recovery
day: 72.5 ± 1.6 nu) power have been observed. The observed
transient increase in HR associated with overall decrease in
HRV (SDNN) suggests an altered sympatho-vagal balance in
response to UfCPs inhalation.
Pulmonary inflammatory response
BALF and lung
BALF derived parameters obtained on first and third
recovery day showed no signs of UfCPs exposure related
inflammatory response in the lungs. Cell numbers and
cell differentials of the BALF (Total cell: control/exposed:
3.7 ± 0.2/4.7 ± 0.2; PMN: control/exposed: 0.3 ± 0.1/0.4
± 0.1) were not affected in exposed SHRs. BALF protein
(control/exposed: 137 ± 32/135 ± 34 μg/ml), albumin
concentrations (control/exposed: 18 ± 5/15 ± 5 μg/ml),
and γ-Glutamyltransferase (GGT; control/exposed: 4.9 ±
0.4/4.8 ± 0.5 U/l) activity were used as markers of pulmo-
nary capillary leakage or pulmonary cell membrane integ-
rity; whereas N-acetyl glucosaminidase (NAG; control/
exposed: 5.3 ± 0.5/5.8 ± 0.7 U/l) activity in BALF indicate
macrophage phagocytic ability. None of these markers
from BALF showed any significant changes in exposed
SHRs. The pulmonary cytokine IL-6 in BALF samples of
exposed SHRs showed a slight, 10% increase (control/
exposed: 83 ± 6.2/92 ± 4.1 pg/ml), but differences were
not statistically significant. Furthermore, transcript profil-
ing markers associated with inflammation (MIP-2, TNF-
α), were assessed from the lung tissues on first and third
recovery day. Corresponding to the findings in BALF,
expression of MIP-2 and TNF-α were not significantly
altered on both days (data not shown).
Pulmonary histopathology
Pulmonary histopathology analysis also revealed no signs
of pulmonary inflammation in the UfCPs exposed animal
group (data not shown).
UfCPs-mediated direct effect on pulmonary and cardiac 
tissue
Pulmonary mRNA expression
Transcript profiling markers associated with oxidative
stress (hemeoxygenase-1: HO-1), endothelial activation
(endothelin-1: ET-1; endothelin recptor A and B: ETA and
ETB), and coagulation factors (tissue factor: TF; plasmino-
gen activator inhibitor-1: PAI-1) were assessed from lung
tissues of control and UfCPs exposed SHRs on first and
third recovery day (Figures 4 a–f, left column) using quan-
titative real time Polymerase Chain Reaction (qRT-PCR).
All of these markers showed a significant induction (~2.5-
fold; p < 0.05) on the third recovery day with ET-1 being
the maximum induced factor (6-fold; p < 0.05). Although
PAI-1 expression was slightly decreased on first day of
recovery, but at third recovery day its expression was
increased over 2-fold in the lung.
Cardiac mRNA expression
To assess whether pulmonary and cardiac tissue exhibited
a comparable response, HO-1, ET-1, ETA, ETB, PAI-1 and
TF were also measured in the cardiac tissues on the first
and third day of recovery. Compared to the lung only
slight but non significant exposure related increases were
detected in the cardiac tissues. Strikingly, HO-1 was
repressed by over 2-fold in the heart in contrast to its more
than 2-fold induction in the lung on the third day of
recovery (Figures 4 a–f, right column).Page 4 of 18
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a Changes in mean blood pressure (mBP) associated with filtered air (control)/ultrafine carbon particles (UfCPs, exposed) exposed SHRsFigur  2
a Changes in mean blood pressure (mBP) associated with filtered air (control)/ultrafine carbon particles 
(UfCPs, exposed) exposed SHRs. mBP increased by 6 mmHg, (4%) on the first and second day of recovery in the UfCPs 
exposed groups compare to control SHRs. * indicates significant difference of mBP (p < 0.05) between exposed (gray)  and 
control (white)  SHRs. 2b: Changes in heart rate (HR) of SHRs associated with filtered air (control)/ultrafine carbon particles 
(UfCPs; exposed) exposure. HR responded with a lag of one day, it increased on the second and third day of recovery by 17 
bpm (5%) in UfCPs exposed SHRs, and reached baseline values on the fourth day of recovery. * indicates significant difference 
of HR (p < 0.05) between exposed (gray) and control (white) SHRs. 2c: Changes in body temperature (T) of SHRs associated 
with filtered air (control)/ultrafine carbon particles (UfCPs; exposed) exposure. 2d: Changes in activity (Act) of SHRs associ-
ated with filtered air (control)/ultrafine carbon particles (UfCPs; exposed) exposure.   The vertical bars exhibit arithmetic 
mean values (mean ± SE) of control (white; n = 7) and exposed (gary; n = 7) groups. Each bar represents a combined mean 
value of: (72 10-minutes segments/12h dark periods/rat) × 7 rats.
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Particle and Fibre Toxicology 2008, 5:19 http://www.particleandfibretoxicology.com/content/5/1/19Cardiac histopathology
Histological analysis revealed fibrotic foci (typical for
SHRs), but no signs of inflammation or cardiomyopathy
following exposure to UfCPs (data not shown).
Systemic response
Acute phase proteins
To assess whether UfCPs exposure induces an inflamma-
tory response at the systemic level the acute phase reac-
tants, C-reactive protein (CRP; control/exposed: 92 ± 3.8/
94 ± 3 μg/ml)), haptoglobin (HP; control/exposed: 300 ±
17/309 ± 20 mg/dl)) and fibrinogen (control/exposed:
190 ± 11.4/198 ± 5.2 mg/dl) were determined from serum
and plasma. None of these markers revealed any signifi-
cant changes in exposed SHRs compared to the control
groups.
Haematology
The complete blood cell count [total red and white blood
cell, haematocrit, platelets, polymorphonuclear neu-
trophil (PMN), and lymphocytes] was assessed on first
and third day of recovery. Most of the blood parameters
were not affected by UfCPs exposure (Table 1), but cell
differentials revealed significant increase (p < 0.05) in the
fraction of neutrophil (control/exposure: 30 ± 2.8/43.3 ±
2.2%) and lymphocyte (control/exposure: 43.3 ± 3.1/56.3
± 2.9%) on the first day of recovery (Table 1).
Renin/Angiotensin
To assess whether the renin-angiotensin system (RAS) is
involved in the observed cardiovascular response (BP and
HR, Figures 2a &2b) following UfCPs exposure we ana-
lyzed plasma renin concentration and activity (Figures 5a
&5b) at several time points from blood samples of the
caudal vein (blood B; Table 2). Measurements of renin
concentration and activity as well as angiotensin (I and II)
concentrations were assayed employing specific radioim-
munoassay [22]. Significant (p < 0.05) increases of
plasma renin concentration were detected on the first and
second day of recovery. Levels returned to baseline values
at the third day of recovery (Figure 5a). However the activ-
ity of renin was not affected by UfCPs exposure (Figure
5b). Additionally, Ang I and II concentrations were also
determined on the first and third day of recovery in blood
samples from the abdominal aorta (blood A; Table 2). A
tendency of increased Ang I and II concentrations were
detected on the first day of recovery in exposed animals;
however the differences remained statistically unaltered
(Figure 5c & d).
Discussion
Exposure to ambient air pollution has been associated
with increased cardiovascular morbidity and mortality [1-
4]. The currently emerging occupational and environmen-
tal burden of UFPs from the rapidly developing field of
nanotechnology evokes concerns about the health effect
of engineered nanoparticles (ultrafine) worldwide. Our
exposure study specifically addresses the action of labora-
tory generated, airborne-like UFPs in the respiratory and
the cardiovascular system as very little is known about the
potential adverse effects and the underlying pathomecha-
nisms. Findings from this work indicate increases in BP
associated with striking activation of plasma rennin angi-
otensin system together with increases in circulating white
blood cells and increased expressions for markers of pul-
monary endothelial activation, blood coagulation, and
oxidative stress in cardiovascular compromised UfCPs-
exposed rats. Because these changes occur at UfCPs con-
centration which does not produce apparent pulmonary
inflammation our results support epidemiological associ-
ations of elevated particle levels and cardiovascular
impairment in individuals with preexisting diseases.
Compared to transient increases of HR and pulmonary
neutrophilic inflammation during UfCPs exposure in
WKY rats [9]; inhalation of UfCPs results in a prolonged
increase in HR and BP in SHRs with a lag of 1–3 days, but
no pulmonary neutrophilic inflammation. Lack of neu-
trophilic influx in association with no significant increase
in MIP-2 and/TNF-α mRNA expression in SHRs suggests
that the observed cardiovascular impairment is relatively
independent of an apparent inflammatory response
although an association to other observed pulmonary and
systemic effects can not be ruled out. The lack of neu-
trophilic inflammation is very unusual as we have noted
this happen in WKY rats similarly exposed to UfCPs [9].
However; it is not totally surprising in SHRs as it has been
shown in some studies that these rats (SHRs) require a
greater insult to initiate inflammation than WKY [23].
Although there is no neutrophilic inflammation in the
lung but significant induction of HO-1, PAI-1, TF and
other markers such as endothelin-1 is an indicator of pul-
monary oxidative stress and injury. Considering this
observation we hypothesize that SHRs (hypertensive indi-
viduals) are at higher risk and more susceptible or vulner-
able to cardiovascular impairments following exposure to
UFCPs compared to healthy WKY as no pulmonary injury
or coagulative changes were observed in WKY similarly
exposed to UfCPs [9].
A series of studies have shown that following exposure
UFPs gain rapid access to pulmonary epithelial, interstitial
and endothelial cells and can also be translocated from
peripheral lungs to systemic circulation and extra-pulmo-
nary organs in a considerable amount [17,24,25]. There-
fore, it is probable that the detected cardiovascular
impairments may primarily be due to the direct interac-
tion of UfCPs with pulmonary tissue and at systemic level
results in oxidative stress, activation of endothelial sys-
tem, induction of blood coagulation factors, and inhibi-Page 6 of 18
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Relative Changes in time domain and frequency domain measures of heart rate variability (HRV) of SHRs associated with fil-tered air (co trol)/ultrafine carbon pa ticles (UfCPs; exposed) exp sureFigure 3
Relative Changes in time domain and frequency domain measures of heart rate variability (HRV) of SHRs 
associated with filtered air (control)/ultrafine carbon particles (UfCPs; exposed) exposure. Bars represent arith-
metic mean values ± SE of control (white bars; n = 7) and exposure groups (gray bars; n = 7): (12 5-minutes segments/12h dark 
period/rat) × 7 rats. Dotted horizontal lines are used to highlight the relative changes. HRV, paralleled changes in HR was 
decreased by about 30% in UfCPs exposed SHRs during the recovery periods (second and third day). *: indicates significant dif-
ferences of HRV (p < 0.05) between exposed (gray) and control (white) SHRs. SDNN: standard deviation of normal to normal 
(NN) intervals. RMSSD: square root of the mean of squared differences between adjacent NN intervals. LF/HF: ratio of the 
absolute powers in the low-frequency (LF: 0.20 Hz to 0.75 Hz) and high-frequency bands HF: 0.75 Hz to 2.5 Hz).
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Changes in the lung and heart transcript levels of haemoygenase-1 (HO-1; a), endothelin-1 (ET-1; b), endothelin receptor A (ETA; c), endothelin receptor B (ETB; d), plasminog n activator inhibitor-1 (PAI-1; e) and tissue factor (TF; f) i  control (fil-tered air) and u trafin  arb n p rti les (UfCPs) exposed SHR  o the first and third recovery dayFigur  4
Changes in the lung and heart transcript levels of haemoygenase-1 (HO-1; a), endothelin-1 (ET-1; b), endothe-
lin receptor A (ETA; c), endothelin receptor B (ETB; d), plasminogen activator inhibitor-1 (PAI-1; e) and tissue 
factor (TF; f) in control (filtered air) and ultrafine carbon particles (UfCPs) exposed SHRs on the first and third 
recovery day. Real time qRT-PCR was performed and the comparative CT method was used for the quantification of fold 
change. Bars represent arithmetic mean values ± SE of control (white bars; n = 6) and UfCPs exposed SHRs on first (light gray 
bars; n = 6) and third recovery day (dark gray bars; n = 6). Lung expression of all other markers (except PAI-1) was not 
affected on the first day of recovery (light gray) – but showed significant inductions on the third day of recovery (dark gray) by 
factors of about 2.5, except for ET-1 which increased about 6-fold. *: Significant (p < 0.05) difference in expression level 
between exposed animals compare to the corresponding control: †: Significant (p < 0.05) difference in expression level 
between exposed SHRs on first (light gray) and third (dark gray) recovery day.
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Particle and Fibre Toxicology 2008, 5:19 http://www.particleandfibretoxicology.com/content/5/1/19tion of fibrinolysis together with induction of renin-
angiotensin system at a systemic level.
UfCPs burden in the lungs and at systemic level
Responses to UfCPs were studied considering particle
number and mass concentrations, which approximate
peak ambient particulate matter burdens [26,27]. Assum-
ing a mean minute ventilation of 214 ml minutes-1 [28]
the rats in this study inhaled 308 liter of aerosol (172 μg
m-3) in 24 h, resulting in an inhaled cumulative dose of
approximately 53 μg UfCPs. It has been shown [29] that
inhalation exposure of rat to ultrafine gold particle (mass
median diameter: 49 nm) under similar conditions results
in an alveolar deposition rate of 20%. Considering this
deposition rate, the alveolar burden of UfCPs in our
present experiment is ~10.6 μg or 5.5 × 1011 particles.
With respect to our previous studies conducted in rats
[17,24] about 20% of the deposited dose, i.e. 2 μg/rat, is
supposed to be rapidly translocated into pulmonary tis-
sues and may exert direct intracellular effects in these tis-
sues. According to the translocation studies [17] much
less than 1 μg may be systemically available and less than
0.1 μg may reach the heart. These dose estimates corre-
sponds to the dose that a healthy human will accumulate
over one year when being exposed to common ambient
levels of insoluble UFPs [30], i.e. 3 × 1011 UFPs will accu-
mulate in the lungs and 6 × 108 UFPs in each of the sec-
ondary target organs (the estimate is based on a particle
concentration of 1 × 103 cm-3, a daily inhaled gas volume
of 1 × 104 l/d, and a deposition fraction in the peripheral
lung of 0.3). However, ambient UFP concentration near
busy roads may exceed the assumed particle number con-
centration substantially up to a factor of 100 [31] and the
deposition fraction may be higher in individuals suffering
from respiratory diseases, e.g. ~70% in asthmatics [32].
This suggest that the biological responses detected in the
present study may be related to peak ambient ultrafine
particle exposures to which humans may incidentally or
accidentally be exposed to.
Cardiophysiological performance
The cardiophysiological response in SHRs was character-
ized by a prolonged increase in BP and HR by about 5%
during first to third day of the recovery period (p < 0.05).
The extent of HR increase in UfCPs-exposed SHRs is con-
sistent with other studies [33,34] and that of our previous
study [9] showing a significant elevation of HR by ~5% in
WKY rats exposed to a comparable UfCPs concentration
(180 μg m-3). However, in our previous study the normo-
tensive (WKY) rats showed only increased HRs during the
exposure period and did not exhibit any changes in BP.
Similarly Gordent et al. [35] reported small but significant
increases of HR (approximately 5%) in healthy rats during
6 h nose-only exposures to concentrated ambient particles
(132 μg m-3-184 μg m-3). In SHRs about 8% increase of
HR has been observed at much higher diesel particle con-
centrations [1000 μg m-3; [33]. Furthermore, the mild but
significant BP increase is comparable with the physiolog-
ical endpoints from F-344 rats after exposure to urban
ambient particles [36]. Overall, BP and HR changes are
admittedly small; however, with respect to the UfCPs
exposure level selected, they are reasonable and likely to
occur also in humans. Comparison of response patterns
in healthy and compromised animals suggests that hyper-
tensive animals are more susceptible to UfCPs particle
exposure than normotensive. We detected a significant
Table 1: Haematological analysis of filtred air (control;n = 8) and ultrafine carbon particles (UfCPs;n = 8) exposed SHRs on first and 
third recovery day.
Parameters First recovery day Third recovery day
Control Exposed Control Exposed
RBC (×103 cells/μl) 7.92 ± 0.36 9.6 ± 0.3 8.29 ± 0.22 9.41 ± 0.11
WBC (×103 cells/μl) 6.19 ± 0.4 5.79 ± 0.5 8.7 ± 0.9 6.6 ± 0.7
PLT (×103 cells/μl) 436 ± 30.2 443.8 ± 48.4 611 ± 22 582 ± 24
Haematocrit (%) 44.8 ± 0.8 43.8 ± 2.1 46 ± 1.2 44 ± 0.4
Thrombocrit (%) 0.51 ± 0.04 0.39 ± 0.05 0.6 ± 0.02 0.45 ± 0.04
Neutrophil (%) 30 ± 2.8 *43.3 ± 2.2 44 ± 1.5 48 ± 2.04
Lymphocyte (%) 43.3 ± 3.1 *56.3 ± 2.9 45 ± 1.5 50 ± 1.9
* Significant difference (p < 0.05) between control and exposed animals RBC: Red blood cells;
WBC: white blood cells; PLT: platelet.Page 9 of 18
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a: Plasma renin concentration (PRC) of control (filtered air) and ultrafine carbon particles (UfCPs) exposed SHRs at several time points: before exposure (baseline), firs , second and third recovery daysFigure 5
a: Plasma renin concentration (PRC) of control (filtered air) and ultrafine carbon particles (UfCPs) exposed 
SHRs at several time points: before exposure (baseline), first, second and third recovery days. Bars represent 
arithmetic mean values &#177 SE of control (white bars; n = 8) and exposure groups (gray bars; n = 8). Significant increases of 
PRC were detected on the first and second day of recovery. *: Significant difference (p < 0.05) of PRC between exposed and 
control SHRs (n = 8/8; control/exposed) on first and second recovery day. 5b: Plasma renin activity (PRA) of control (filtered 
air) and ultrafine carbon particles (UfCPs) exposed SHRs at several time points: before exposure (baseline) and first, second 
and third recovery days. Bars represent arithmetic mean values &#177 SE of control (white bars; n = 8) and exposure groups 
(gray bars; n = 8). 5c: Plasma angiotensin I (Ang I) concentration of control (filtered air) and ultrafine carbon particles (UfCPs) 
exposed SHRs on first and third recovery day. Bars represent arithmetic mean values &#177 SE of control (white bars; n = 8) 
and exposure groups (gray bars n = 8). 5d: Plasma angiotensin II (Ang II) concentration of control (filtered air) and ultrafine car-
bon particles (UfCPs) exposed SHRs on first and third recovery day. Bars represent arithmetic mean values &#177 SE of con-
trol (white bars; n = 8) and exposure groups (gray bars n = 8). Increased values of angiotensin II were detected on the first day 
of recovery but differences are not statistically significant.
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Particle and Fibre Toxicology 2008, 5:19 http://www.particleandfibretoxicology.com/content/5/1/19increase in BP and HR in SHRs over a period of 3 days
after exposure to UfCPs. Whereas in other studies with
uncompromised animal model, alteration of cardiovascu-
lar perfomance (HR and/or BP) was noted during the
exposure and the values reach baseline levels rapidly after
exposure [9,33,35].
Pulmonary and systemic inflammatory responses
A series of epidemiological studies have shown that expo-
sure to ambient ultrafine particles is associated with pul-
monary inflammation caused by deposition of particles in
the alveoli [10,37]. Particle exposure may results in local
and systemic inflammatory responses [6,11] and ulti-
mately may lead to an activation of the coagulatory sys-
tem [18,19], increased plasma viscosity [12], vascular and
endothelial dysfunction [14,15]. Therefore, we assessed
pulmonary and systemic inflammatory responses in order
to shed light on pathophysiological pathways, which
might be the plausible cause of UfCPs induced cardiovas-
cular effects. No apparent inflammatory response has
been detected in pulmonary tissue but a low grade inflam-
matory reaction cannot be ruled out. Plasma level of acute
phase proteins such as HP and CRP were not affected by
UfCPs exposure, but the observed small increases in the
fraction of neutrophils and lymphocytes following 24 h
exposure to UfCPs may indicate a small degree of systemic
inflammation. Similar observations have been made by
others and such phenomenon are suggested to contribute
to the progression of atherosclerosis, hypertension and
increased the risk of cardiopulmonary disease [38,39].
The precise mechanism(s) of how systemic impairment is
produced by inhalation of UfCPs and its consequence on
cardiophysiology need to be explored.
Pulmonary and extra-pulmonary effects unrelated to 
inflammation
The pulmonary response of exposed SHRs is characterized
by a significant induction of HO-1 (~2.5-fold), a sensitive
marker for UfCPs mediated oxidative stress [40,41], on
the third day of recovery. The induced HO-1 is an indica-
tor of a host defense mechanism for oxidative stress and is
likely to be directly activated by UfCPs which have been
shown to provide a substantial oxidative potency [42].
The observed induction of PAI-1 (~2.5-fold) can be con-
sidered to be a downstream effect of particle induced oxi-
dative stress [43]. Increased levels of PAI-1, have been
Table 2: Experimental design of cardiophysiological, pulmonary and systemic response
Study Day -2 Day -1 Day 0 Day 1 Day 2 Day 3 Day4 Day5
Adaptation Baseline Exposure Recovery
Cardiophysiological Response*
Telemetry (n = 7) Acclimatization √ √ √ √ √ √
No change BP↑ BP↑ HR↑ HR↑
Pulmonary response
BALF (n = 6) √ √
Lung tissue (n = 6) √ √
Pulmonary histopathology (n = 2) √ √
Systemic Response
Blood A (n = 8) √ √
Blood B (n = 8) √ √ √
Heart tissue (n = 6) √ √
Cardiac histopathology (n = 2) √ √
* Cardiophysiological response by telemetry: individuals served as their own control. Pulmonary and systemic response: number of exposed 
animals is given. A similar number of animals was exposed to filtered air and served as controls. Total animal number: 39. Blood A: blood collected 
from retro arbitral sinus and abdominal aorta, Blood B: blood collected from caudal vein. BP↑, HR↑: blood ressure or heart rate significantly 
elevated after UfCPs exposure, respectively. √: performed.Page 11 of 18
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and are a common denominator of increased risk for car-
diovascular disease [44]. PAI-1 is known to be an inhibi-
tor of fibrinolysis and regulator of vasoactivity [45], thus,
increased levels of PAI-1 mRNA expression may also be
involved in the observed increase in BP. Further, an
increased TF expression (~2.5-fold) was detected in the
lungs. Increased TF levels have been related to an
increased risk of cardiac events because induction of TF is
highly correlated with thrombogenesis and endothelial
dysfunction [46,47]. Activation of TF, the extrinsic coagu-
lation pathway, in association with impaired fibrinolysis
via PAI-1 activation suggests that UfCPs exposure induces
endothelial dysfunction and activates the coagulatory
pathway, both of which are correlated with overall cardi-
ovascular risk [45-47].
Additionally, induction of ETA and ETB (~2.5-fold) along
with a 6-fold induction of pulomonary ET-1 further sup-
ports the notion of an UfCPs induced endothelial dys-
function in the pulmonary circulation. The simultaneous
increase in ETA and ET-1 indicates a synergistic effect
because ET-1 contributes to endothelial dysfunction pre-
dominantly via ETA receptor stimulation [48]. Potential
health implications are obvious since several reports
imply that both ETA and ETB are contributing to ET-1
induced hypertension [49,50]. Moreover, up-regulation
of ETB receptors is most notable in heart failure, hyperten-
sion and in artherosclesis formation [51].
Hence, the observed induction of the endothelin system
(ET-1, ETA and ETB) and increased expression of coagula-
tory factors (PAI-1 and TF) in pulmonary tissue suggests
that UfCPs exposure triggers important pathophysiologi-
cal pathways in the lungs which have been associated with
impaired cardiovascular performance and an increases
risk for cardiovascular events.
Interestingly, in the heart of UfCPs exposed SHRs, the
only marker being affected was the oxidative stress-induc-
ible defense enzyme HO-1. Expression of HO-1 mRNA
was more than 2-fold repressed in contrast to its up-regu-
lation in the lung tissue. Our data do not allow to provide
a final explanation for this observation, but under
hypoxic conditions HO-1 mRNA is reported to be
induced by a number of studies while others found a
repression [52]. It was suggested that the differential regu-
lation and the different expression levels of HO-1 repre-
sent an adaptation or unrecognized defense strategy to
stress and that the response can differ depending on cell
and tissue type [52,53]. Accordingly, we may value the dif-
ferent regulations observed for HO-1 in lung and cardiac
tissue in the present study. However, we have to specify
that we do not have any hint that UfCP exposure results in
hypoxic conditions in cardiac tissue.
Systemic effects associated with cardiopulmonary 
impairments
The most interesting UfCPs-mediated systemic effect is
the close association of increased BP in exposed SHRs
(Figure 2a) with a significant increase of circulating PRC
at the same time points (Figure 5a). The tendency of
increased Ang I and II concentrations on the first day of
recovery further supports the notion that the RAS is pri-
marily involved in the UfCPs-mediated BP increase
detected in exposed SHRs [54-56]. On the other hand, the
enzymatic activity of renin appears not to be affected by
UfCPs exposure. Renin is a rate-limiting enzyme deter-
mining the overall RAS activity. It converts plasma angi-
otensinogen to Ang I, which is subsequently converted to
Ang II, one of the most powerful vasoconstrictor. The RAS
system is typically associated with the perfusion of the
kidney, however, several recent studies reported that local
RAS exist which is physiologically active in different tis-
sues like lung, heart, kidney, or brain [55,57,58]. Besides
regulating regional perfusion, local RAS may also play an
important role in regulating systemic blood pressure
[55,57,58]. Therefore, induced RAS in plasma might be
due to direct effect of UfCPs in the pulmonary tissue,
resulting in local RAS activation and systemic blood pres-
sure elevation.
Conclusion
We have shown that inhalation of UfCPs at concentra-
tions reflecting peak ambient exposures results in a mod-
erate (about 5%) increase in HR and BP in SHRs with a lag
of 1–3 days which is paralleled by the induction of renin-
angiotensin system in plasma, potentially being due to an
activation of the local pulmonary rennin-angiotensin sys-
tem. Specifically in pulmonary tissue markers of oxidative
stress (HO-1), the endothelin system (ETA, ETB and ET-1)
and the coagulation system (PAI-1 and TF) were found to
be activated by UfCPs exposure. Since various inflamma-
tory markers in pulmonary tissues (TNF-α, MIP-2; IL-6)
were not affected and neutrophil cell recruitment was not
observed, the UfCPs induced effects appear to be unre-
lated to a traceable pulmonary inflammation. At the sys-
temic level different inflammatory markers (acute phase
protein: CRP, HP) were also not affected, but the observed
increases in neutrophils and lymphocytes following 24 h
exposure to UfCPs suggest a possible low degree of sys-
temic inflammation. Therefore, our findings imply that
UfCPs exposure at levels below detectable pulmonary
inflammation triggers distinct effects in pulmonary tissues
and at systemic levels that can promote further cardiovas-
cular impairment in SHRs. Since dose estimates revealed
that the burden of UfCP delivered to the rats exceeds that
caused by common urban levels in humans the observed
biological effects may only be related to peak ambient
ultrafine particle exposures, e.g. at busy rods, to which
humans are incidentally or accidentally be exposed to.Page 12 of 18
(page number not for citation purposes)
Particle and Fibre Toxicology 2008, 5:19 http://www.particleandfibretoxicology.com/content/5/1/19Based on the response detected in SHRs – as a model for
impaired cardiovascular individuals – as well as those
observed in healthy WKY rats [9] we reciprocate the epide-
miological findings that predisposed individuals are at
higher risk and more susceptible to cardiovascular impair-
ments following exposure to UfCPs than healthy ones.
Methods
Animals
Male spontaneously hypertensive rats (SHR; 6 month)
were used for the present study. Animals were housed
under filtered air and specific pathogen free (SPF) condi-
tions at a mean temperature of 22 ± 2°C, a mean relative
humidity of 50 ± 5%, and a 12 h light-dark cycle (6 a.m.
to 6 p.m. light on) with pelleted feed and filtered water
being supplied ad libitum. Experimental protocols were
approved by the Animal Care and Use Committee of the
HelmholtzZentrum München – German Research Center
for Environmental Health and by the Bavarian Animal
Research Authority (211-2531-88/2001).
Ultrafine carbon particle generation and whole body 
exposure chamber
The methodology of UfCPs generation and the setup of
the whole body exposure system for rodent have been pre-
viously described [9,59]. UfCPs showed a monomodal
number distribution in the exposure chamber with a
median particle size ± arithmetic SD of 31 ± 0.3 nm. Meas-
ured mass and number concentration was 172 μg m-3 and
9× 106cm-3, respectively. This translates into a surface area
concentration of 0.139 m2(particle) m-3 (air) because the
mass specific surface area (according to the BET method)
of the UfCPs was determined to be 807 m2 g-1. Based on
the polydispersity of the particle distribution (geometric
standard deviation is 1.51) a median mass diameter of 46
nm is calculated.
Experimental design
Table 2 provides an overview of the experimental design.
Primarily, the cardiophysiological responses, i.e. effects
on HR and BP were measured in 7 SHRs following 24 h
UfCPs inhalation exposure using a radio telemetry sys-
tem. Since BP and HR were increased on first to third day
of recovery, the subsequent exposures were conducted in
additional, non-telemetry SHRs to obtain blood, BALF
and tissue samples from the first and third day of recovery.
Each exposure used 16 SHRs, 8 animals were exposed to
filtered air (controls) while the other 8 animals were
exposed to UfCPs for 24 h (exposed). In the first study,
animals were sacrificed in the morning of the first day of
recovery. Prior to BALF collection, blood samples (blood
A) of 8 SHRs were collected from retro orbital sinus for
analysis of haematological parameters and from the
abdominal aorta for analysis of biomarkers. Six animals
were used to collect BALF and tissue samples (heart and
lung) for further assessment of pulmonary and systemic
response, the remaining 2 SHRs of each group were used
for pulmonary and cardiac histopathology. Animal distri-
bution and sample collection of the control group was
similar to that of the exposed group.
In the second inhalation study, SHRs were sacrificed in
the morning on third day of recovery. Blood sampling
from retro orbital sinus and abdominal aorta (blood A),
BALF and tissue samples collection, as well as cardiac his-
topathology were carried out as described above. In addi-
tion, 400 μl of blood from the caudal vein of each animal
(blood B) was collected in the morning before exposure
(base line) and on the first, second and third day of recov-
ery to assess plasma renin concentration and activity.
Cardiophysiological analysis by radiotelemetry
Exposure protocol
Cardiophysiological response prior to and following
inhalation exposure to UfCPs was performed on 7, 6
months old SHRs (360 ± 11 g) by using radio telemetric
system as described in our previous study [9] (Dataquest
A.R.T; Data Sciences International D.S.I., St. Paul MN,
U.S.A). The implantation of telemetric devices into the
peritoneal cavity of animals was performed as previously
described [9]. All animals exhibited rapid post surgical
recovery, with resumption of normal food and water
intake within 24 h of surgery. They returned to presurgical
body weight (excluding the weight of the implant) on
average within 3–4 days and did not exhibit any signs of
post surgical complications. After 10 days of post surgical
recovery, the animals were acclimatized in the exposure
chamber for two days (day -2 and day -1). We have
observed that following 2 days of acclimatization in the
exposure chamber prior to the actual data recording cardi-
ovascular response (BP and HR) reaches to its baseline
values. Data recording was then initiated and continued
for six days (Figure 1), that included a baseline reading
(day 0), exposure (day 1), and recovery period readings
(days 2–5).
In this study the individual animals served as their own
controls. Applying the above defined exposure protocol
animals were primarily exposed to filtered air (control)
and 4 weeks later to UfCPs by whole-body exposure. A
time gap of 4 weeks was chosen to ensure elimination of
any possible effects of clean air exposure. Comparison of
baseline values between 6 and 7 months old SHRs indi-
cate that cardiac performance was not altered by the 4
week time gap between control and exposure conditions
(see baseline values in results). Moreover, no significant
changes of cardiovascular performance (mBP and HR; Fig-
ures 2a and 2b) was noted in SHRs following exposure to
filtered air.Page 13 of 18
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telemetry system
The implantation of telemetric devices into the peritoneal
cavity of animals (n = 7), the radio telemetric data acqui-
sition and analysis were performed as described previ-
ously [9].
Briefly, arterial BP, HR, body core temperature (T), and
physical activity (Act) of SHRs were continuously col-
lected over 24 h/day, throughout baseline, exposure and
recovery periods. Systolic (sBP), diastolic (dBP), and
mean (mBP) arterial blood pressure were determined
from the BP tracings on a beat to beat basis. The data of
each animal were then processed to obtain 10-minutes
average segments per rat for each of the measured param-
eters (Figure 1). For the final data analysis, we only have
considered the values of each parameter from the 12 h
dark period (6 p.m. to 6 a.m.), as animals are more active
during the night time. Thereby, 72 consecutive values of
10-minutes data segments were obtained per rat per day
and per parameter. Since we did not observe a time
dependency of particle associated effects during the 12 h
period in each of the exposed animals, mean values were
used for further data processing. For all of the measured
parameters, we averaged the 72 values obtained for each
day resulting in one mean value per parameter per rat and
per day. Based on these values, group mean averages were
calculated on a daily bases for the whole study and were
used for statistical comparison between filtered air (con-
trol) and UfCPs exposed SHRs.
For heart-rate variability (HRV) analysis, a different proce-
dure has to be applied [9]. For the 12 h dark periods, one
5-minutes ECG segment per hour was randomly selected
and used for further HRV analysis. For each of these 5-
minutes segments the standard deviation of all adjacent
normal sinus NN intervals (SDNN) was determined as a
measure of the overall HRV. In addition, the square root
of the mean of squared differences between adjacent nor-
mal to normal intervals (RMSSD) and the low-frequency
to high-frequency ratio (LF/HF), reflecting the balance of
cardiac parasympathetic tone and sympathetic activity,
respectively, were determined. Further data processing to
obtain daily averages for each of the rats and group aver-
ages followed the procedure described above for the other
parameters.
Assessment of UfCPs-mediated pulmonary inflammatory 
response
BALF and lung
BALF analysis was performed as described in our previous
study [9]. In brief, one aliquot of whole BALF (n = 6) was
used for determining total cell counts (Coulter Counter;
Coulter, Inc., Miami, FL), and a second aliquot was centri-
fuged (Cytospin 2; Shandon, Astmoor, UK) to counts cell
differential. Macrophages, polymorphonuclear cells
(PMNs, or neutrophil), eosinophil, and lymphocyte were
counted using light microscopy (over 200 cells counted
per slide). The remaining BALF was centrifuged (1500 × g)
to remove cells, and the supernatant fluids were analyzed
for protein, albumin concentration and γ-Glutamyltrans-
ferase (GGT), N-acetyl glucosaminidase (NAG) activity as
potential biological markers for pulmonary capillary leak-
age and lung injury [60]. Furthermore, transcript profiling
markers associated with pulmonary inflammation (MIP-
2, TNF-α), were assessed from the lung tissues (n = 6)
using real-time RT-PCR (see gene expression analysis).
Pulmonary histopathology
The left lung of each non lavaged animal (n = 2) was
infused via left main bronchus by 4% buffered formalin at
20 cm water pressure for 20–30 minutes. The main bron-
chus was then tied and the lung was submerged in fixative
until processing for histology. Paraffin blocks were pre-
pared from dehydrated tissues and 3- to 4-μm sections
were stained with hematoxylin and eosin for light micro-
scopic evaluation of the pulmonary tissues [9].
Assessment of UfCPs-mediated effects on pulmonary and 
cardiac tissue
Gene expression analysis
For gene expression analysis lung and heart tissues were
collected from each animals (n = 6) immediately after
BALF collection, placed in vials and flash frozen in liquid
nitrogen. They were then stored at -80°C until extraction
of RNA.
RNA isolation
Total RNA was extracted from these tissue samples using
the RNeasy (lung) or RNeasy fibrous tissue (heart) kits
and protocols obtained from Qiagen. RNasin Plus
(Promega), a broad spectrum RNase inhibitor, was added
to each sample immediately after isolation from the tis-
sue. Concentration and purity of the RNA samples were
determined with the NanoDrop ND-100 spectrophotom-
eter (NanoDrop Technologies). Aliquots of each sample
were diluted to a concentration suitable for PCR and the
stock samples and dilutions were stored at -80°C.
Gene expression assays
Relative quantification of gene expression was determined
using real-time qRT-PCR on the Applied Biosystems Inc.
model ABI 7900 HT Sequence Detection System. Gene-
specific primers for control and target genes were pur-
chased from Applied Biosystems Incorporated (Table 3).
The reagent kit used was the SuperScript III Platinum One-
Step Quantitative RT-PCR System purchased from Invitro-
gen. Reverse transcription and amplification conditions
were as follows: 53°C for 20-minutes, 95°C for 2-min-
utes, and 40 cycles at 95°C for 15 seconds and 60°C forPage 14 of 18
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into Microsoft Excel for normalization of target gene data
to the control gene and for the calculation of fold changes
in gene expression.
Cardiac histopathology
The whole heart of each non lavaged animal (n = 2) was
submerged in fixative until processing for histology. Par-
affin blocks were prepared from dehydrated tissues and 3-
to 4-μm sections were stained with hematoxylin and eosin
for light microscopic evaluation of the cardiac histopa-
thology [9].
Assessment of UfCPs-mediated systemic response
Haematological analysis, measurement of different
biomarkers from plasma and serum were used for the
assessment of systemic response following UfCPs expo-
sure. Blood samples (blood A, Table 2) of each animal
were collected from retro orbital sinus (haematology) and
from abdominal aorta (biomarkers) on first and third day
of recovery. For analysis of plasma renin concentration
and activity, blood samples (blood B, Table 2) were also
collected from caudal vein at several time points.
Haematology
For haematological analysis, 500 μl of blood sample from
retro orbital sinus of each animal (blood A, n = 8) was col-
lected in EDTA-Microvette and analysed by using haema-
tology analyzer (Bayer ADVIA 120, Germany).
Acute phase proteins analysis
Blood samples collected from each animals (blood A, n =
8) were stored in aliquots of 2.6 ml in 2.9 ml S-Monovette®
tube (Sarstedt, Germany) with or without anticoagulant
(citrate and EDTA) for further analysis of different mark-
ers. Each blood sample with anticoagulant was centri-
fuged (at 2710 g) for 10-minutes (4°C) for the collection
of plasma sample and stored at -80°C until analysed.
Fibrinogen concentration was measured from each
plasma samples as previously described [60]. C-reactive
protein (CRP) and haptoglobin (HP) were analysed from
serum collected from blood samples by centrifugation for
15-minutes (at 1300 g, 4°C). CRP and HP were measured
by using kit from DiaSorin Inc. (Stillwater, MN) for con-
trols and standards, except the standard for CRP, which
was obtained from Kamiya Biomedical Company (Seattle,
WA).
Renin/Angiotensin analysis
Related to the limited amount of blood which can be
taken repeatedly from a rat, blood samples collected from
caudal vein (blood B, n = 8) before exposure, on the first,
second, and third day of recovery were used to analyse
only plasma renin concentration and activity. In this case
400 μl of blood samples from each animal were collected
from the caudal vein in a 2 ml Eppendorf cup containing
25 μl mixture of 2.5 ml EDTA (Merck, Germany) and 25
μl of Phenantrolin (Calbiochem, Germany).
Furthermore concentration of angiotensin I (Ang I) and
angiotensin II (Ang II) were determined from plasma on
first and third recovery day. For this purpose blood sam-
ples were collected from abdominal aorta (blood A, n = 8)
in a 5 ml falcon tube containing mixture (140 μl/ml
blood) of p-hydroxy-mercuribenzoic acid (10 μl, Sigma),
phenyl-methyl-sulfonyl-fluoride (10 μl, Sigma), EDTA
(50 μl), pepstatin A (20 μl, Sigma) and o-phenanathrolin
(50 μl, Merck). Measurements of renin activity and con-
centration as well as angiotensin (I and II) concentrations
were assayed employing specific radioimmunoassays, as
previously described [22].
Statistics
After checking for the normal distribution assumption the
differences between exposure and control groups were
compared by using the t-test. Cardiovascular response
parameters were described by a linear mixed regression
model for repeated measurements. Based on this model
group differences between the exposure and control group
were tested. For expression analysis of various parameters
from lung and heart tissues, a two-way analysis of variance
(ANOVA) was used to analyze differences between the
groups. However, for the plasma rennin and angiotensin
(I and II) data the normailtiy assumption does not hold.
Therefore, for plasma rennin and angiotensin (I and II)
concentration the Wilcoxon rank sum test was performed.
P values less than 0.05 were stated as statistically signifi-
cant. All computations were done by the software pack-
ages Statgraphics plus v5.0 (Manugistics, Rockville, MD)
and SAS V9.1 (Cary, NC). Data are presented as arithmetic
mean values of n observations ± the standard error (SE),
unless otherwise indicated.
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